Remove 2007 Remove Safety Remove Sales
article thumbnail

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

pharmaphorum

It is, however, the first that can be substituted across all Lucentis’ five indications and to be fully interchangeable – which means it is considered to have no clinically meaningful difference compared to the reference drug in safety, purity, or potency and can be substituted for it without any prescriber intervention.

FDA 59
article thumbnail

Veeva Systems Summit, Madrid – pharmaphorum reflects

pharmaphorum

Founded in 2007 by Peter Gassner, a luminary of Silicon Valley with a net worth of circa $5.25 Prioritisation and the evolution of the sales, medical, and marketing triumvirate. Sales, medical, and marketing evolving together and building medical content creates communication and an agility to work with commercial partners.

Pharma 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK approves prescription-only melatonin drug for childhood ADHD

Pharmaceutical Technology

Melatonin has remained prescription-only in countries such as the UK and New Zealand, with Australia only allowing over the counter sale of melatonin since 2021. In 1995, the UK government classified it as a medicine making its over-the-counter sale illegal. In the study, 48.8% with the placebo group.

article thumbnail

Japan’s M&A Boom

Pharmaceutical Technology

“The business integration from 2005 to 2007 of the two separate companies to form the joint Daiichi Sankyo created one of Japan’s biggest pharmaceutical companies.” “Ranbaxy led the way with eight acquisitions and is aspiring to be a $2bn company by 2007.” % increase over the previous year.

article thumbnail

Interview: Dr Alan S Louie – US Food and Drug Administration Delays

Pharmaceutical Technology

Yes there has been some slowing in the approval of drugs from the FDA, in part due to legitimate concerns in relation to drug safety. In terms of concerns over safety, it has meant that the FDA has been essentially very cautious in moving forward. Some of that funding is going towards other efforts, including food safety.